Summary
Elevance Health, Inc. (formerly Anthem, Inc.) announced the closing of a significant debt offering on September 9, 2019, raising approximately $2.473 billion in net proceeds. This offering consisted of three tranches of notes: $850 million of 2.375% Notes due 2025, $825 million of 2.875% Notes due 2029, and $825 million of 3.700% Notes due 2049. The company intends to utilize these funds for general corporate purposes, including working capital, share repurchases, debt repayment, and potential acquisitions. This strategic move indicates a proactive approach by Elevance Health to strengthen its financial position and provide flexibility for future growth initiatives. Investors should note the specific maturity dates and coupon rates of each note series, as well as the company's redemption options and the conditions that could trigger an offer to repurchase the notes, such as a change of control coupled with a credit rating downgrade.
Key Highlights
- 1Elevance Health closed a $2.473 billion debt offering consisting of three note series: $850M (2.375% due 2025), $825M (2.875% due 2029), and $825M (3.700% due 2049).
- 2Net proceeds from the offering are approximately $2,473 million after underwriting discounts and expenses.
- 3Proceeds are earmarked for general corporate purposes, including working capital, share repurchases, debt repayment, and funding acquisitions.
- 4The Notes are registered under the Securities Act of 1933, as amended.
- 5The Indenture governing the Notes allows for the incurrence of additional indebtedness by the Company and its subsidiaries.
- 6The company has the right to redeem the notes prior to their maturity dates under specific conditions, with varying call protection periods and premium calculations.
- 7An offer to repurchase Notes at 101% of principal value will be triggered by a change of control coupled with a downgrade below investment grade by major rating agencies.